PR Newswire
BRIDGEWATER, N.J., Aug. 3, 2023
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Second Quarter of 2022 --
-- Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Million to $305 Million --
-- Topline Data from Post-Marketing ARISE Study of ARIKAYCE Expected in September of 2023 --
-- Blended Blinded Dose Titration Data for TPIP in PH-ILD and PAH Expected in Second Half of 2023 --
-- Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remains on Track to Read Out in the Second Quarter of 2024 --
BRIDGEWATER, N.J., Aug. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
"The second quarter of 2023 demonstrated the strongest quarter of ARIKAYCE sales since launch, reflecting positive momentum in the U.S. and earlier than anticipated signs of growth in Japan," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "In the midst of this strong commercial performance, we are preparing for a series of data readouts that we hope will drive shareholder value and meaningful outcomes for patients. Leveraging our growing commercial business, mid- to late-stage pipeline assets, and early-stage research efforts, we are strategically constructing what we hope will be the next leading and self-sustaining biotechnology company."
Recent Pillar Highlights
Pillar 1: ARIKAYCE
Pillar 2: Brensocatib
Pillar 3: TPIP
Pillar 4: Early-Stage Research
Second-Quarter 2023 Financial Results
Balance Sheet, Financial Guidance, and Planned Investments
Conference Call
Insmed will host a conference call beginning today at 8:30 AM Eastern Time. Shareholders and other interested parties may participate in the conference call by dialing (646) 960-0278 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the Company's website at www.insmed.com.
A replay of the conference call will be accessible approximately 1 hour after its completion through September 3, 2023, by dialing (647) 362-9199 (U.S. and international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com.
INSMED INCORPORATED | |||||||
Consolidated Statements of Net Loss | |||||||
(in thousands, except per share data) | |||||||
(unaudited) | |||||||
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, | ||||
| 2023 | | 2022 | | 2023 | | 2022 |
| | | | | | ||
Product revenues, net | $ 77,229 | | $ 65,221 | | $ 142,443 | | $ 118,328 |
| | | | | | | |
Operating expenses: | | | | | | | |
Cost of product revenues (excluding amortization of intangible assets) | 16,594 | | 16,395 | | 30,424 | | 28,586 |
Research and development | 196,969 | | 88,527 | | 324,834 | | 172,883 |
Selling, general and administrative | 84,431 | | 59,974 | | 164,345 | | 116,722 |
Amortization of intangible assets | 1,263 | | 1,263 | | 2,526 | | 2,526 |
Change in fair value of deferred and contingent consideration liabilities | 13,500 | | (12,622) | | 4,000 | | (24,240) |
Total operating expenses | 312,757 | | 153,537 | | 526,129 | | 296,477 |
| | | | | | | |
Operating loss | (235,528) | | (88,316) | | (383,686) | | (178,149) |
| | | | | | | |
Investment income | 11,172 | | 835 | | 21,696 | | 972 |
Interest expense | (20,619) | | (3,357) | | (40,622) | | (6,648) |
Change in fair value of interest rate swap | 1,184 | | - | | (349) | | - |
Other expense, net | (488) | | (4,306) | | (599) | | (5,555) |
Loss before income taxes | (244,279) | | (95,144) | | (403,560) | | (189,380) |
| | | | | | | |
Provision for income taxes | 530 | | 501 | | 1,013 | | 886 Werbung Mehr Nachrichten zur Insmed Inc Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |